Join Our Mission.
Become an Investor.
We are now offering a pre-IPO investment opportunity, open to both accredited and non-accredited investors under a Regulation A+ offering.
A Smarter Model for Cancer Therapy
Why Us?
Why Now?
With deep expertise in drug development and a mission to advance high-impact therapeutics from academia, Jabez is positioned to deliver value across 3 crucial fronts: patients, academic innovators, and the oncology industry.
How?
While much of the field chases high-throughput discovery, we believe cancer drug development can’t be industrialized.
Breakthroughs come from deep biological insight and rigorous disease modeling – the kind of work that lives in academia.
Our model is designed to partner with universities and push their innovations forward. With the right capital, we can transform academic discoveries into real-world impact – quickly, strategically, and at scale.
Patients need this.
Academia needs this.
The industry needs this.
And We Need You!
our trusted partners
Lead Investors
Investors
What People Are Saying About Jabez
get started
Become an Investor
get started
There are several ways to initiate the process of becoming an investor:
Click the ‘Get Started’ button to fill out the form to receive our full investment package, offering details, and next steps for securing your place in this groundbreaking opportunity.
You can also give us a call and speak to a member of our team to learn how you can become a member of the Jabez investor group.
FAQs
Have questions about investing in Jabez Biosciences? We’ve compiled answers to some of the most common questions from prospective investors below.
Who can invest?
This opportunity is open to both seasoned investors and individuals new to private biotech offerings.
How will my investment be used?
What is the exit strategy for investors?
How is Jabez's approach different?
OFFERING TYPE:
Regulation A+ Tier II
$2.00/SHARE
$5,000 minimum
Offering Size
$10,000,000
We’re raising up to $10M to fuel our next major inflection points across R&D and commercialization.
Who can invest?
Accredited & Non-Accredited
This opportunity is open to both seasoned investors and individuals new to private biotech offerings.
Use of funds:
Capital will support clinical validation, regulatory milestones, and go-to-market readiness of our lead candidate JBZ-001.
Clinical development
Research & Development
Regulatory Approvals
Market Expansion
our team
Jabez Leadership
our team
Tamara Jovonovich, PhD
CEO & Co-Founder
Tamara is a highly experienced biotech operator with over 20 years in pharmaceutical development and 15 FDA drug approvals
Robert Lewis
COO & Co-Founder
Rob Lewis has over 30 years in pharmaceutical development and has overseen 30 FDA drug approvals.
Featured Video
Jabez Biosciences: A Smarter Model for Cancer Therapy
- Video Overview
The biotech industry is pouring billions into AI platforms and supercomputers to reinvent drug discovery from scratch. But when it comes to cancer, there’s a faster, more cost-effective way: tap into the massive reservoir of high-quality, target-validated research already emerging from academia.
our roadmap
Our Story & Milestones
our roadmap
Phase 1 Readiness
Our DHODH inhibitor, JBZ-001, is Phase I ready with comprehensive pre-clinical data supporting its therapeutic potential
IND Filing
We filed an Investigational New Drug (IND) application to the FDA, marking a significant milestone in our development process.
JBZ-001: Study Start
First patient dosed in Phase 1 clinical trial of JBZ-001 marking a major milestone.
Special Designation
We aim to achieve FDA Fast-Track designation, priority review, and Orphan-Drug status for JBZ-001, expediting the review process.
Market Launch
Following successful trials and regulatory approvals, we plan to launch JBZ-001, delivering it to cancer patients throughout the US.
Latest
News & Events
- 06.23.25
- News
Multi-institutional team awarded NCI grant to open novel AML trial
- 05.09.25
- News
Jabez Biosciences, Inc. Announced Phase 1 Clinical Trial of JBZ-001 at AACR 2025
- 04.03.25
- News
Jabez Biosciences, Inc. Announces First Patient Dosed in Phase 1 Oncology Clinical Study of JBZ-001
get started
Become an Investor
get started
There are two main ways to initiate the process of becoming an investor:
Book a video call to speak to our CEO, Tamara Jovonovich 1-on-1 to discuss the company’s upcoming plans, overall mission, and dreams for the future.
1/3
Give us a call and speak to a member of our team to learn how you can become a member of the Jabez investor group.
2/3
Sign up to our mailing list and to receive regular updates on our progress, events, insights, and new ways to invest.
3/3
FAQs
Have questions about investing in Jabez Biosciences? We’ve compiled answers to some of the most common questions from prospective investors below.
Who can invest?
Have questions about investing in Jabez Biosciences? We’ve compiled answers to some of the most common questions from prospective investors below.
How will my investment be used?
What is the exit strategy for investors?
How is Jabez's approach different?
Legal Disclaimers
Forward-Looking Statements: This website and its materials may contain forward-looking statements regarding future events, projections, and business strategies. These statements are subject to significant risks and uncertainties and should not be relied upon as guarantees of future performance.
Investment Risk: Investing in early-stage biotech companies involves risk, including the potential loss of principal. There is no guarantee of an IPO, liquidity event, or return on investment. Please consult with a financial advisor before making any investment decisions.
SEC Qualification: This Regulation A+ offering is made pursuant to an offering statement that has been qualified by the U.S. Securities and Exchange Commission (SEC). However, the SEC has not approved or endorsed the merits of this offering. Potential investors should review all offering materials carefully before investing.
No Offer or Solicitation: This webpage does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. The offering is made solely through the official offering circular available at Jabezbio.com
I’ve known and worked with Tamara Jovonovich and Robert Lewis for about 20 years. They both individually excelled at drug development and portfolio analysis and had a keen sense when it came to thinking outside the box. It’s no surprise to me that they are making great strides developing their own products now. I expect nothing but great things for Jabez!
Janet DeLeon DeLeon Pharmaceutical Consulting, LLC